Sanofi

Innate Pharma

Angela Virone-Oddos

Laurent Gauthier

Marielle Chiron

Marielle Chiron Blondel

Béatrice Cameron

Cendrine Lemoine

Nicolas Gourdin

Elisabeth Remy

Alessandro Masiero

Klervi Desrumeaux

Sambasiva Rao

Jonathan Kingsbury

Yanfeng Zhou

Alexandre Tang

Alain Fournier

Leila Sevigny

Ingo Focken

Brian Murray

Jochen Beninga

Nathan Ostberg

Helene Bonnevaux

Sanket Patke

Marco Meloni

Zichuan Zhang

Jacques Dumas

The present disclosure provides antigen-binding proteins specifically binding GPRC5D, as well as respective antibodies in enhanced ADCC formats, and methods of using them to treat cancers such as multiple myeloma.

Anti-GPRC5D antibodies and compositions

The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-γ receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including multiple myeloma (MM).

Natural killer (NK) cell engagers binding to NKp46 and BCMA variants with Fc-engineering

The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-&#x3b3; receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS).

Multifunctional natural killer (NK) cell engagers binding to NKp46 and CD123

Provided herein are antibodies that specifically bind human CD38, formulations and unit dosage forms comprising the antibodies, methods of preparing the antibodies and methods of using the antibodies.

Anti-CD38 antibodies and formulations

Growing community of inventors

Paris, France

Angela Virone-Oddos